HilleVax, Inc. (HLVX), a clinical-stage biopharmaceutical company focused on novel vaccines, announced Thursday the appointment of Sean McLoughlin as Chief Operating Officer.
He succeeds co-founder and current Chief Operating Officer, Dr. Aditya Kohli, who will remain a full-time executive with the company as Chief Business Officer. Kohli will be responsible for business development and corporate strategy.
McLoughlin holds three decades of commercial and operational experience in vaccines. He was at GSK for over 25 years, most recently as the Global Vaccine Commercialization Lead, RSV at GSK. Prior to that, he held the position of New Product Strategy Lead, Vaccines Business Unit at GSK.
Rob Hershberg, Chairman and Chief Executive Officer of HilleVax, said, "We are excited to welcome Sean to HilleVax's executive team as we continue to progress NEST-IN1, our Phase 2b clinical trial of HIL-214 for the prevention of moderate-to-severe norovirus-related acute gastroenteritis."
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.